UCB has launched Neupro for PD and restless legs; Relday moves into clinical trials;

> UCB has launched Neupro, its transdermal rotigotine delivery system, in the U.S. for the treatment of idiopathic Parkinson's disease and restless legs syndrome. Press release

> R-Tech Ueno and Tohoku University are developing an ocular drug delivery system for R-Tech Ueno's isopropyl unoprostone for the treatment of retinitis pigmentosa. Press release

> BioTime has signed an exclusive sublicense and supply agreement with Jade Therapeutics for an ophthalmological therapeutic sustained-release drug delivery platform, HyStem hydrogels. Press release

> Zogenix has started a clinical trial for Relday, which combines risperidone with its DosePro needle-free, subcutaneous drug delivery system. Press release

> Delivering dexamethasone via Mercator's micro-infusion catheter inhibits restenosis for at least 9 months in peripheral vascular disease (PAD). Press release

> MedPro Safety Products has signed a letter of intent with an undisclosed specialty pharmaceutical company to license its drug delivery platform, including an automated passive safety syringe. Press release

> Fucose-bound nanoparticles could target anticancer drug delivery to pancreatic cancer cells. Abstract

And Finally… Drugs could be delivered by remote control--an implantable drug delivery device has successfully delivered hormone treatment under wireless control. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.